Press release archive

29 March 2011
GSK and Valeant receive European authorisation for Trobalt (retigabine)

28 March 2011
GSK publishes 2010 Corporate Responsibility Report

23 March 2011
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction

22 March 2011
GSK launches London 2012 initiative with King’s College London to inspire young people into science careers

18 March 2011
GSK supports recovery efforts to help those affected by the Japan earthquake

14 March 2011
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease

11 March 2011
GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint

09 March 2011
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus

04 March 2011
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board

02 March 2011
Regulatory update: Nimenrix® (MenACWY vaccine)

02 March 2011
GSK outlines new plan to drive recruitment and attract graduate talent in the UK

01 March 2011
Reward for charities bridging gaps in health care provision

01 March 2011
World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth

25 February 2011
David Redfern appointed as new Chairman of ViiV Healthcare

11 February 2011
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism

08 February 2011
GlaxoSmithKline moving to new building at Philadelphia Navy Yard

07 February 2011
GSK revises US Avandia label to include new restrictions on use

07 February 2011
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet

03 February 2011
GSK results announcement for the fourth quarter

03 February 2011
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD

01 February 2011
GSK announces the sale of its entire shareholding in Quest Diagnostics

01 February 2011
Update on Pandemrix™ and interim Finnish report on narcolepsy

28 January 2011
GSK and Actelion discontinue clinical development of almorexant

26 January 2011
GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication

24 January 2011
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma

21 January 2011
Regulatory update - GSK and Valeant receive positive opinion in Europe from the CHMP for Trobalt (retigabine)

19 January 2011
GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication

19 January 2011
GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza

17 January 2011
GlaxoSmithKline announces Q4 2010 legal charge

12 January 2011
GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK’786, formerly Traficet-EN™, for the treatment of Crohn’s disease

07 January 2011
GlaxoSmithKline and DENTSPLY International sign global agreement to create a portfolio of co-branded professional oral care products

02 January 2011
GSK responds to 60 Minutes

21 December 2010
GlaxoSmithKline and Theravance commence MABA Phase IIb COPD study

16 December 2010
GlaxoSmithKline and Impax Pharmaceuticals enter global agreement to develop and commercialise a late stage compound for Parkinson’s Disease

16 December 2010
Andrew Witty appointed Lead Non-Executive Board Member for the Department for Business, Innovation and Skills (BIS)

13 December 2010
GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition

10 December 2010
Phase III study in HER2-positive advanced breast cancer shows overall survival benefit when Tykerb is combined with paclitaxel

10 December 2010
Data from Tykerb investigational phase III studies in neo-adjuvant HER2-positive breast cancer presented at breast cancer symposium

07 December 2010
GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China

03 December 2010
GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta® PDUFA target date to 10th March 2011

01 December 2010
Avodart reviewed by FDA advisory committee for prostate cancer risk reduction

01 December 2010
GSK and Valeant announce receipt of U.S. FDA Complete Response letter for ezogabine

29 November 2010
Government patent box proposals ‘transform’ UK attractiveness for investment

29 November 2010
GlaxoSmithKline to increase its shareholding in Theravance

26 November 2010
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia

16 November 2010
Human Genome Sciences and GlaxoSmithKline announce vote of FDA advisory committee to recommend approval of Benlysta® for systemic lupus erythematosus

15 November 2010
New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients

12 November 2010
GlaxoSmithKline and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases

29 October 2010
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal

29 October 2010
GSK and Amicus Therapeutics enter exclusive worldwide agreement to develop and commercialise Amigal™ for Fabry disease

26 October 2010
GSK completes previously reported settlement with U.S. Department of Justice regarding former manufacturing plant

21 October 2010
GSK announces Q3 results for 2010

18 October 2010
GSK outlines approach to delivering advances in the treatment of rare diseases

18 October 2010
GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases

14 October 2010
GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine

04 October 2010
GSK takes minority stake in newly formed Convergence Pharmaceuticals

30 September 2010
GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine)

29 September 2010
GlaxoSmithKline receives EU approval for a new therapeutic indication for Arixtra® (fondaparinux)

23 September 2010
GSK regulatory update on Avandia following EMA and FDA reviews

23 September 2010
GSK EU regulatory update on Pandemrix™

22 September 2010
GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair™ development programme

16 September 2010
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications

15 September 2010
Three-year results from ECLIPSE study indicate that COPD patients may require prevention strategies to manage exacerbations, regardless of disease severity

11 September 2010
GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain

08 September 2010
GlaxoSmithKline and Genmab announce start of ofatumumab Phase III combination study in non-Hodgkin’s lymphoma

08 September 2010
GSK announces succession plan for Chief Financial Officer

08 September 2010
Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia

08 September 2010
GSK signs agreement with Lonza to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio

06 September 2010
BBC Panorama – 6 September 2010: “A Risk Worth Taking?” Programme. GlaxoSmithKline Right of Reply Statement

06 September 2010
GlaxoSmithKline pre-broadcast statement: BBC Panorama, 6 September 2010

06 September 2010
GlaxoSmithKline responds to British Medical Journal article regarding Avandia® (rosiglitazone)

02 September 2010
Reports of narcolepsy in Europe following vaccination with Pandemrix™

30 August 2010
GSK and Valeant announce new U.S. FDA PDUFA goal date for ezogabine

23 August 2010
GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles

19 August 2010
GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus

09 August 2010
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia

05 August 2010
Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance

29 July 2010
GSK exercises option on Anacor’s novel antibiotic for the treatment of gram-negative infections

23 July 2010
GSK receives CHMP positive opinion for a new indication for Arixtra

21 July 2010
GlaxoSmithKline statement in response to FDA announcement on TIDE trial

21 July 2010
GSK announces Q2 results for 2010

15 July 2010
GlaxoSmithKline legal update

14 July 2010
GlaxoSmithKline statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone)

13 July 2010
GlaxoSmithKline (GSK) responds to Senate Finance Committee letter of 12 July to FDA

09 July 2010
Data support Avandia (rosiglitazone maleate) cardiovascular safety profile

09 July 2010
GSK EU regulatory update on Avandia (rosiglitazone)

02 July 2010
GSK and EDB commit $35 million (USD) in funding to support research in green and sustainable manufacturing in Singapore

01 July 2010
GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreement

01 July 2010
GlaxoSmithKline creates a new operating unit dedicated to expanding access to medicines for people living in the world’s poorest countries

01 July 2010
GSK and Aptuit finalise agreement for Aptuit to acquire GSK’s research operations in Italy

23 June 2010
GlaxoSmithKline receives EU authorisation for a new therapeutic indication for Tyverb® (lapatinib)

23 June 2010
GlaxoSmithKline enters agreement with Medivir for exclusive rights to cold sore treatment Xerclear™

15 June 2010
GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib)

14 June 2010
FDA approves Jalyn™, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate

11 June 2010
GlaxoSmithKline Receives Complete Response from FDA for Candidate Meningococcal and Hib Combination Vaccine

10 June 2010
GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix

10 June 2010
Regulatory update – BLA filed for Benlysta® (belimumab)

07 June 2010
Regulatory update - Benlysta® (belimumab)

02 June 2010
GSK announces revised product labels for Serevent and Advair

21 May 2010
European Medicines Agency maintains position on the continued use of Rotarix™ (rotavirus vaccine)

20 May 2010
Viani (Seretide): German patent litigation update

19 May 2010
New research identifies promising leads to follow in search for medicines to fight malaria

14 May 2010
FDA says Healthcare Providers can resume use of Rotarix (Rotavirus Vaccine, Live, Oral)

11 May 2010
Patrick Vallance appointed to GSK executive leadership team

11 May 2010
GSK extends presence in Asia with new strategic alliance in South Korea

07 May 2010
GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines

28 April 2010
GSK announces Q1 results for 2010

20 April 2010
GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta™ in systemic lupus erythematosus

19 April 2010
GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra® (ofatumumab)

31 March 2010
GSK and Isis Pharmaceuticals collaborate on RNA therapeutics for rare and infectious diseases

31 March 2010
GSK receives European approval for Duodart®

29 March 2010
GSK regulatory update – Avodart (dutasteride)

26 March 2010
Updated GlaxoSmithKline statement on European regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine)

26 March 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

23 March 2010
GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world’s poorest countries

22 March 2010
GSK announces succession plan for leadership of Consumer Healthcare business

22 March 2010
GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine)

22 March 2010
GlaxoSmithKline announces Swiss approval of Duodart®

19 March 2010
GlaxoSmithKline commences Relovair Phase III asthma programme

16 March 2010
GSK publishes 2009 Corporate Responsibility Report

12 March 2010
GlaxoSmithKline receives marketing authorisation in the EU for Revolade® (eltrombopag)

12 March 2010
GSK commences succession plan for management of vaccines business

08 March 2010
GSK CEO Andrew Witty dedicates albendazole facility in Nashik to WHO’s Global Programme to Eliminate LF

24 February 2010
GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia

20 February 2010
GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia

20 February 2010
GSK rejects conclusions reported in The New York Times story on Avandia

19 February 2010
GSK receives positive opinions in Europe for Tyverb® (lapatinib) and Votrient™ (pazopanib)

18 February 2010
GSK statement on FDA’s proposed label revisions for some asthma medicines

18 February 2010
GSK Consumer Healthcare warns consumers of potential health risks associated with long-term excessive use of zinc-containing denture adhesives

17 February 2010
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS

04 February 2010
GSK launches new specialist unit to research and develop medicines for rare diseases

04 February 2010
GSK announces appointment of Philippe Fauchet as President of GSK Japan

04 February 2010
Results announcement for the fourth quarter 2009

29 January 2010
GSK’s Tykerb® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer

27 January 2010
Rotarix™ significantly reduced severe rotavirus gastroenteritis in African babies during their first year of life

20 January 2010
GSK announces ‘open innovation’ strategy to help deliver new and better medicines for people living in the world’s poorest countries

18 January 2010
GSK contributes to Haiti relief efforts

15 January 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

12 January 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

11 January 2010
GSK exercises option to progress development of ChemoCentryx’s Traficet-EN for the treatment of inflammatory bowel diseases

18 December 2009
Revolade (eltrombopag) receives positive opinion in Europe for chronic immune thrombocytopenic purpura

16 December 2009
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment

14 December 2009
GSK publishes speaking, consulting fees paid to US healthcare professionals

11 December 2009
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer

11 December 2009
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines

10 December 2009
Pre-Budget Report response - GSK comments on ‘patent box’

09 December 2009
GSK initiates second pivotal Phase III trial for investigational cardiovascular medication Darapladib

01 December 2009
GSK Update: GSK’s Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization

01 December 2009
GSK completes extension of strategic collaboration with Aspen

30 November 2009
GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed

30 November 2009
Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan

24 November 2009
GlaxoSmithKline and Gilead announce agreement to commercialise Viread® for chronic hepatitis B in key Asian countries

23 November 2009
GSK Regulatory Update: Avodart

23 November 2009
Pandemic 2009 Influenza Update: Pandemrix™ data in children and adolescents from 3 to 17 years of age

16 November 2009
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction

10 November 2009
Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine

10 November 2009
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries

09 November 2009
Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)

09 November 2009
GlaxoSmithKline and XenoPort announce extension of GSK1838262 (XP13512) FDA review date to 9 February, 2010

06 November 2009
World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine

03 November 2009
World’s largest malaria vaccine trial now underway in seven African countries

03 November 2009
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care

02 November 2009
Retigabine Regulatory Update

02 November 2009
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus

28 October 2009
Results announcement for the third quarter 2009

27 October 2009
Pandemic 2009 Influenza Update: Pandemrix™ data in an elderly population

27 October 2009
GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD

26 October 2009
GSK and Genmab receive accelerated approval for Arzerra™

23 October 2009
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK’s H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results

20 October 2009
GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for Benlysta in systemic lupus erythematosus

19 October 2009
FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer

16 October 2009
FDA approves Cervarix, GlaxoSmithKline’s cervical cancer vaccine

16 October 2009
Pandemic (H1N1) 2009 Influenza Update: Results from second clinical trial of GSK’s H1N1 adjuvanted vaccine confirm immune response and tolerability

16 October 2009
GSK’s Cervarix® becomes the first cervical cancer vaccine to gain approval in Japan

13 October 2009
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy

13 October 2009
GSK partners with UK Government and Wellcome Trust to stimulate innovation through the creation of a world-class science park

12 October 2009
GSK’s Avodart® / tamsulosin combination showed benefits for men with prostate enlargement

08 October 2009
GlaxoSmithKline and U.S. Patent and Trademark Office file a motion to dismiss litigation over Final Regulations

06 October 2009
GSK expands presence in China through strategic cooperation to form a joint venture on paediatric vaccines

06 October 2009
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine

05 October 2009
GlaxoSmithKline receives unanimous FDA Panel approval recommendation for Votrient™

05 October 2009
Positive phase II results for GSK1838262 (XP13512) reported for subjects with post-herpetic neuralgia and a history of inadequate response to gabapentin

01 October 2009
Avodart (dutasteride) regulatory update

30 September 2009
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives European Commission Approval

29 September 2009
GlaxoSmithKline update on FDA review of Cervarix

29 September 2009
Fatality reported in UK HPV vaccine immunisation programme

28 September 2009
GSK and UPCH to launch Lucozade across China

28 September 2009
GSK provides update on regulatory filings for Zunrisa/Rezonic

25 September 2009
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives positive opinion from European Regulators

14 September 2009
Pandemic (H1N1) 2009 Influenza Update: Initial results from first clinical trial of GSK’s H1N1 adjuvanted vaccine

14 September 2009
Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects

09 September 2009
FDA Advisory Committee makes favorable recommendation for Cervarix, GlaxoSmithKline’s candidate cervical cancer vaccine

17 August 2009
GlaxoSmithKline and Genmab announce results from a study of Arzerra in rituximab refractory follicular NHL

17 August 2009
GSK and Brazil’s Fiocruz form partnership for new R&D effort and increased vaccine access

14 August 2009
Pandemic (H1N1) 2009 influenza update

13 August 2009
Shionogi-GlaxoSmithKline Pharmaceuticals acknowledges position of the European AIDS Treatment Group and the AIDS Treatment Activists Coalition to revise protocol for ING112276, a clinical study for S/GSK1349572

04 August 2009
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine

29 July 2009
GlaxoSmithKline and Genmab announce top-line results for ofatumumab in rheumatoid arthritis

29 July 2009
Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)

27 July 2009
Amgen to collaborate with GSK to commercialize denosumab in Europe for postmenopausal osteoporosis (PMO)

22 July 2009
GlaxoSmithKline completes acquisition of Stiefel

22 July 2009
Results announcement for the second quarter 2009

22 July 2009
Pandemic (H1N1) 2009 Influenza Update

21 July 2009
GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics

21 July 2009
Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study

20 July 2009
Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus

14 July 2009
GSK announces new commitments to fight HIV/AIDS in Sub-Saharan Africa - special focus on care and treatment of children

09 July 2009
WHO grants prequalification to Cervarix®: GSK’s vaccine to help combat cervical cancer in developing nations

08 July 2009
Alnylam joins GSK in donating intellectual property to patent pool for neglected tropical diseases

07 July 2009
Landmark study for GSK’s cervical cancer vaccine published in The Lancet

02 July 2009
GSK further extends its product portfolio in the Middle East and North Africa

26 June 2009
Seretide: Irish patent litigation update

23 June 2009
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs

23 June 2009
Regulatory update for REZONIC™ (casopitant mesylate)

16 June 2009
FDA extends review of Arzerra™ (ofatumumab)

15 June 2009
GSK announces a strategic alliance with Dr. Reddy’s to further accelerate sales growth in emerging markets

12 June 2009
GlaxoSmithKline update: A (H1N1) influenza

09 June 2009
GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China

05 June 2009
Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines

05 June 2009
World Health Organization grants Global Prequalification to GSK’s Rotarix™ vaccine

05 June 2009
Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders

02 June 2009
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs

01 June 2009
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer

29 May 2009
FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)

22 May 2009
US Department of Health and Human Services (HHS) purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant system

15 May 2009
GlaxoSmithKline update: A (H1N1) influenza vaccine development

12 May 2009
GSK extends strategic collaboration with Aspen

08 May 2009
Community healthcare charities receive £300,000 from GlaxoSmithKline in recognition of their work

06 May 2009
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million

01 May 2009
GlaxoSmithKline update: influenza A (H1N1)

27 April 2009
Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease

27 April 2009
Emergence of a new H1N1 influenza A strain (swine influenza)

20 April 2009
GlaxoSmithKline launches alli® (orlistat 60 mg)

20 April 2009
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business

16 April 2009
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company

01 April 2009
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US

31 March 2009
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation

30 March 2009
Cervarix® U.S. regulatory update

24 March 2009
GSK publishes 2008 Corporate Responsibility Report

19 March 2009
GlaxoSmithKline announces sale of shares in Quest Diagnostics Inc.

05 March 2009
NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)

04 March 2009
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer

17 February 2009
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

06 February 2009
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV

05 February 2009
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer

05 February 2009
Results announcement for the fourth quarter 2008

04 February 2009
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma

02 February 2009
GlaxoSmithKline plc, announces board changes

30 January 2009
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer

30 January 2009
Deirdre Connelly to join GSK as President, North American Pharmaceuticals

29 January 2009
GSK announces charges for legal matters

29 January 2009
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

23 January 2009
GSK to drive growth in emerging markets with acquisition of UCB products

22 January 2009
GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe

21 January 2009
GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)

09 January 2009
GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome

23 December 2008
GlaxoSmithKline and Archemix form strategic alliance to develop aptamers to treat inflammatory diseases

22 December 2008
GlaxoSmithKline to cease providing corporate political contributions

08 December 2008
GlaxoSmithKline extends tender offer for Genelabs Technologies, Inc.

08 December 2008
Two new studies in the New England Journal of Medicine show malaria vaccine candidate advancing in Africa

21 November 2008
GSK and Neptunus sign cooperation agreement to form joint venture for the co-development of flu vaccines in China, Hong Kong and Macau

20 November 2008
Cervarix, GSK’s cervical cancer vaccine, wins tender for Dutch national immunisation programme

23 October 2008
GlaxoSmithKline and AFFiRiS sign an exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines

22 October 2008
Results announcement for the third quarter 2008

21 October 2008
GlaxoSmithKline to acquire the leading dry mouth brand, Biotene

15 October 2008
GSK’s Emerging Markets strategy advances with acquisition in Egypt

14 October 2008
GSK responds to NICE’s second technology appraisal consultation document on the use of Tyverb, in combination with capecitabine, for women with previously treated advanced or metastatic breast cancer

08 October 2008
LF Elimination programme treats over half billion people and protects millions more from debilitating disease

19 September 2008
GSK update on FDA review of Promacta® (eltrombopag)

16 September 2008
New data for GlaxoSmithKline’s pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning

16 September 2008
GSK and Xenoport announce submission of new drug application requesting FDA approval of Solzira™ for Restless Legs Syndrome

14 September 2008
Tyverb® demonstrates encouraging results in Phase II study in advanced head and neck cancer

12 September 2008
ESMO 2008 - GlaxoSmithKline to present encouraging new data supporting late stage development programme

10 September 2008
GlaxoSmithKline and Cellzome announce major strategic alliance

28 August 2008
GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement for retigabine

24 July 2008
GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration to enable the discovery of new medicines

23 July 2008
Results announcement for the second quarter 2008

23 July 2008
GSK enters transformational agreement with Aspen to drive growth in emerging markets

07 July 2008
GSK receives BITC CommunityMark for global community programmes

30 June 2008
GlaxoSmithKline responds to FDA on Cervarix® and plans to submit final study data for approval

18 June 2008
Cervarix™, GSK’s cervical cancer vaccine, wins tender for UK national immunisation programme

18 June 2008
GlaxoSmithKline responds to Government announcement on the PPRS

16 June 2008
GlaxoSmithKline and Mpex Pharmaceuticals form alliance to develop novel efflux pump inhibitors for use against serious gram-negative infections

15 June 2008
Revolade® (eltrombopag) data presented at EHA: updated data for EXTEND plus new data for REPEAT and DELPHI studies

12 June 2008
GlaxoSmithKline receives marketing authorisation in the EU for Tyverb® (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer

06 June 2008
GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc., a world leader in sirtuin research and development

03 June 2008
GlaxoSmithKline and Boston’s Immune Disease Institute put scientists head-to-head in race for new discoveries

02 June 2008
GlaxoSmithKline successfully completes tender offer for shares of Sirtris Pharmaceuticals

01 June 2008
New data offer insights into the potential role for Tykerb® / Tyverb® (lapatinib) in non-cytotoxic chemotherapy-based treatment regimens

30 May 2008
New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma

29 May 2008
GlaxoSmithKline announces new drug application and Phase III results for Rezonic™ / Zunrisa™ (casopitant)

22 May 2008
GlaxoSmithKline announces $500,000 in fellowships at Stanford Graduate School of Business

21 May 2008
GlaxoSmithKline plc - results of AGM

20 May 2008
Elesclomol study shows significant improvement in progression-free survival for chemotherapy-naïve patients with metastatic melanoma

19 May 2008
First pre-pandemic vaccine approved to help protect against pandemic influenza

16 May 2008
GSK announces results of first Phase III trial evaluating Tykerb®/Tyverb® (lapatinib) plus Herceptin® (trastuzumab)

15 May 2008
The battle against obesity: European experts and pharmacists call for an increased role for pharmacy

14 May 2008
Scientists publishing in Nature call for the diversification of antiviral stockpiles in preparation for an influenza pandemic

14 May 2008
Cervarix™ provides longest duration of sustained neutralising antibodies reported for any vaccine against HPV 16 and 18 to date

02 May 2008
GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals

30 April 2008
FDA approves Advair 250/50 for reduction of exacerbations in patients with COPD

30 April 2008
GSK announces changes to Corporate Executive Team

29 April 2008
GlaxoSmithKline awards £300,000 to community health charities in recognition of their work

25 April 2008
GlaxoSmithKline's Volibris (ambrisentan) receives authorisation from the European Commission for the treatment of Functional Class II and III Pulmonary Arterial Hypertension

25 April 2008
GSK receives positive opinion for conditional approval of new oral breast cancer treatment, Tyverb (lapatinib)

23 April 2008
Results announcement for the first quarter 2008

22 April 2008
GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development

22 April 2008
GlaxoSmithKline gains approval for co-administration of Avodart® (dutasteride) with tamsulosin for the treatment of benign prostatic hyperplasia under the European Mutual Recognition Procedure

22 April 2008
GlaxoSmithKline reports further progress of oncology portfolio

17 April 2008
GlaxoSmithKline and Regulus Therapeutics form strategic alliance to develop microRNA targeted therapeutics to treat inflammatory diseases

15 April 2008
Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine

08 April 2008
GlaxoSmithKline confirms receipt of FDA letter on regulatory reporting

04 April 2008
FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine licensed to complete the rotavirus immunisation series by four months of age

18 March 2008
Tyverb (lapatinib) European regulatory update

16 March 2008
Phase III study of Bosatria (mepolizumab) showed disease control with reduced corticosteroid use in hypereosinophilic syndrome

03 March 2008
FDA grants Priority Review For Promacta / Revolade (Eltrombopag)

29 February 2008
Update on GSK's malaria treatments: Dacart and Lapdap

28 February 2008
XenoPort and GlaxoSmithKline report positive top-line results of final pivotal trial of XP13512/GSK1838262 for restless legs syndrome

26 February 2008
GlaxoSmithKline statement: Public Library of Science Medicine article on antidepressant medicines

26 February 2008
GlaxoSmithKline and Theravance announce expansion of the Horizon programme with start of large Phase 2B study of LABA in COPD patients

21 February 2008
GSK's Volibris (ambrisentan) receives EMEA positive opinion for approval to treat class II and II pulmonary arterial hypertension (PAH)

19 February 2008
New price reductions for GSK antiretrovirals in the world's poorest countries

08 February 2008
Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia

08 February 2008
FDA extends review of NDA for Entereg® (alvimopan)

07 February 2008
Full-year results announcement 2007

06 February 2008
GlaxoSmithKline responds to findings in ACCORD study

04 February 2008
GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer

04 February 2008
GlaxoSmithKline and Amira Pharmaceuticals enter global agreement for FLAP inhibitor programme

31 January 2008
GlaxoSmithKline files pneumococcal paediatric vaccine in the EU

28 January 2008
GlaxoSmithKline welcomes European guidance that stockpiling more than one antiviral would be useful in preparing for a flu pandemic

28 January 2008
GlaxoSmithKline and Synta announce elesclomol granted US orphan drug designation by the FDA

24 January 2008
GSK appoints Lon Cardon to focus genetics on new disease targets

24 January 2008
GSK and MRC to identify new therapeutic targets and biomarkers from genetic association studies

24 January 2008
GlaxoSmithKline and TB Alliance renew tuberculosis drug discovery programme

24 January 2008
GlaxoSmithKline and Medicines For Malaria Venture announce new collaboration to investigate novel antimalarial compounds

24 January 2008
GlaxoSmithKline to revise Avandia® (rosiglitazone maleate) label in Europe following assessment by CHMP

23 January 2008
GlaxoSmithKline and Adolor report favourable FDA Advisory Committee meeting for Entereg® (alvimopan) for the management of postoperative ileus in bowel resection

15 January 2008
New allergic rhinitis treatment Avamys™ approved in Europe

15 January 2008
GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262

03 January 2008
GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and LABA studies for asthma in the Horizon programme

28 December 2007
First head-to-head study comparing common treatments for patients with COPD shows quality of life and survival benefits for patients treated with Seretide

20 December 2007
GlaxoSmithKline files for FDA approval of Promacta/Revolade (eltrombopag) to be the first oral platelet growth factor for rare blood disorder

19 December 2007
GlaxoSmithKline and Santaris Pharma enter global R&D alliance to discover, develop and commercialise RNA antagonists as novel antivirals

19 December 2007
GlaxoSmithKline completes acquisition of Reliant Pharmaceuticals

17 December 2007
GlaxoSmithKline receives FDA ‘complete response’ letter for cervical cancer vaccine

16 December 2007
GlaxoSmithKline announces data on Tykerb® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases

14 December 2007
GlaxoSmithKline, via its Centre Of Excellence for External Drug Discovery, exercises its options to further develop and commercialise Exelixis’ anti-cancer C-Met inhibitior XL880

13 December 2007
GlaxoSmithKline presents innovative neuroscience pipeline

11 December 2007
GlaxoSmithKline responds to JAMA article on the ICES thiazolidinediones and cardiovascular outcomes in older patients with diabetes

10 December 2007
GlaxoSmithKline receives decision from US FDA on Requip® XL™

10 December 2007
Long-term safety and efficacy data on Promacta™ (eltrombopag) presented at American Society of Hematology Annual Meeting

10 December 2007
GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance to develop cancer stem cell antibody therapeutics

10 December 2007
GlaxoSmithKline and Galapagos enter strategic alliance to develop novel antibacterials and antivirals

07 December 2007
GlaxoSmithKline announces appointments to the Board of Directors

06 December 2007
GSK’s continued commitment to fighting HIV/AIDS results in approval of new formulations of three medicines for the treatment of children

04 December 2007
Statement from GlaxoSmithKline: publication of update regarding thiazolidinediones to treatment guidelines for the management of type 2 diabetes mellitus by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA)

03 December 2007
GSK response to Nature Medicine article on rosiglitazone and bone in mice

28 November 2007
GSK statement on US Food and Drug Administration Pediatric Advisory Committee recommendations regarding salmeterol

26 November 2007
GlaxoSmithKline obtains exclusive US OTC marketing rights to Mevacor® (lovastatin) from Merck & Co., Inc.

23 November 2007
New data published in The Lancet show GSK's rotavirus vaccine Rotarix offers sustained and broad protection against all common circulating rotavirus types

21 November 2007
GlaxoSmithKline to acquire Reliant Pharmaceuticals

20 November 2007
GlaxoSmithKline and Genmab initiate ofatumumab rheumatoid arthritis Phase III programme

15 November 2007
GSK and the European Foundation for the Study of Diabetes (EFSD) commit €1 million to diabetes research in Europe

14 November 2007
GlaxoSmithKline revises US labeling for Avandia

07 November 2007
Prometheus to acquire Lotronex® from GlaxoSmithKline

05 November 2007
GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to investigate the potential to aid hepatitis C patients in achieving sustained virological response

05 November 2007
New innovation grants boost malaria advocacy efforts in Africa

02 November 2007
Fabre Kramer Pharmaceuticals receives decision from FDA on gepirone ER for major depressive disorder

24 October 2007
Results announcement for the third quarter 2007

23 October 2007
GlaxoSmithKline and Tolerx form worldwide collaboration for development and commercialisation of novel medication

19 October 2007
New allergic rhinitis treatment Avamys™ receives positive opinion in Europe

18 October 2007
European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment

17 October 2007
New Lancet study: Malaria vaccine candidate has promising safety, tolerability profile in infants

15 October 2007
GSK receives approval for Hycamtin® (topotecan) capsules for the treatment of relapsed small cell lung cancer

10 October 2007
GlaxoSmithKline and Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology

08 October 2007
GlaxoSmithKline appoints Andrew Witty CEO designate

08 October 2007
GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry

04 October 2007
GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe

02 October 2007
GSK applies for licence to market OTC weight loss product In Europe

28 September 2007
GSK submits Cervarix licence application to Japan's health authorities

28 September 2007
GlaxoSmithKline plc announces change to the Board of Directors

27 September 2007
GlaxoSmithKline helps form the Serious Adverse Events Consortium

25 September 2007
GlaxoSmithKline named to Working Mother "100 Best Companies" list

24 September 2007
Cervarix, GSK's cervical cancer vaccine, approved In Europe

21 September 2007
GSK receives decision from FDA on Lamictal®XR™ Extended-Release Tablets

11 September 2007
GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia

11 September 2007
GlaxoSmithKline responds to JAMA articles

04 September 2007
Study shows combination therapy incorporating Avodart® and tamsulosin provides continuous symptom improvement over two years

03 September 2007
GlaxoSmithKline's Arixtra® receives European authorisation for the treatment of acute coronary syndromes

28 August 2007
FDA accepts for review complete response to approvable letter for Entereg® (alvimopan) for POI

28 August 2007
GlaxoSmithKline receives approval for Atriance® (nelarabine) in Europe for the treatment of difficult-to-treat leukaemias and lymphomas

16 August 2007
GlaxoSmithKline signs contract for its pandemic flu vaccine with UK Government

14 August 2007
GlaxoSmithKline's application for Rotarix® is accepted for review by the FDA

14 August 2007
GlaxoSmithKline updates prescribing information for Avandia in the US

08 August 2007
GSK gives consent under Canada's Access to Medicines Regime for generic version of HIV/AIDS medicine for use in Rwanda

08 August 2007
GSK receives decision from FDA on Advair 500/50 for COPD

03 August 2007
GlaxoSmithKline receives new HHS order for H5N1 bulk antigen

02 August 2007
FDA issues second approvable letter for Trexima™

02 August 2007
GSK comments on UK Government announcement to renegotiate current Pharmaceutical Pricing and Regulation Scheme agreement

30 July 2007
GlaxoSmithKline presents Avandia data to FDA

30 July 2007
Pharmetrics epidemiology study

30 July 2007
FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US

27 July 2007
GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis [1]

27 July 2007
GlaxoSmithKline and Targacept form alliance in therapeutics for CNS-related disorders

25 July 2007
New head-to-head study comparing Lexiva® and atazanavir show similar efficacy and lipid changes

25 July 2007
Results announcement for the second quarter 2007

18 July 2007
GSK's cervical cancer candidate vaccine Cervarix™ receives positive opinion in Europe for prevention of cervical cancer

17 July 2007
GSK responds to online review of rosiglitazone by The Cochrane Collaboration

09 July 2007
GSK receives extended licence indication for Seretide in Europe following submission of TORCH data for COPD

27 June 2007
Largest cervical cancer vaccine efficacy trial shows Cervarix™ provides excellent protection against lesions caused by most common cancer-causing virus types

25 June 2007
GlaxoSmithKline's Arixtra® (fondaparinux sodium) receives positive opinion in Europe for the treatment of acute coronary syndromes

24 June 2007
New data show patients treated with Avandia® (rosiglitazone maleate) incurred lower medical costs and used fewer healthcare resources when compared to patients treated with sulphonylureas

22 June 2007
GlaxoSmithKline's Atriance (nelarabine) receives positive opinion in Europe for the treatment of rare, difficult to treat leukaemias and lymphomas

18 June 2007
GlaxoSmithKline expects to launch up to five major new medicines for oncology in next three years

15 June 2007
GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)

13 June 2007
GlaxoSmithKline, Imperial College London, and The Medical Research Council officially open the UK's world-leading Clinical Imaging Centre

13 June 2007
GlaxoSmithKline to make unprecedented vaccine donation to WHO pandemic flu stockpile

13 June 2007
GlaxoSmithKline's application for DTaP-IPV vaccine is accepted for review by the FDA

12 June 2007
alli™ - the OTC weight loss product - on shelves nationwide in the US later this week

12 June 2007
FDA grants priority review for oral formulation of HYCAMTIN (topotecan) to treat relapsed small cell lung cancer

11 June 2007
GlaxoSmithKline and Adolor update alvimopan (Entereg/Entrareg) development programme

09 June 2007
Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP

06 June 2007
Newly published data from large study support cardiovascular safety of Avandia (rosiglitazone maleate)

06 June 2007
Statement of Moncef Slaoui, PhD, Chairman Research & Development, GlaxoSmithKline

05 June 2007
Encouraging clinical activity of GSK's novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer

05 June 2007
Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age

05 June 2007
Interim data from RECORD study show no significant difference between Avandia and standard therapy in risk of cardiovascular hospitalization or death

05 June 2007
GlaxoSmithKline response to New England Journal of Medicine editorials

04 June 2007
GSK's pazopanib shows positive results in patients with advanced renal cell carcinoma, ovarian cancer and soft tissue sarcoma

04 June 2007
Eight-year long-term data demonstrate prolonged overall survival and length of disease remission with BEXXAR

03 June 2007
GlaxoSmithKline reports positive new data on Tykerb (lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) annual meeting

01 June 2007
GlaxoSmithKline announces Altargo approved in Europe for treatment of Impetigo and other skin infections

01 June 2007
GlaxoSmithKline honours cancer research pioneer Gianni Bonadonna with new ASCO award and fellowship

30 May 2007
Data affirms Avandia (rosiglitazone maleate) cardiovascular safety profile

25 May 2007
Retrospective observational study shows combination vaccines may improve vaccination coverage rates in infants

24 May 2007
GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai

23 May 2007
GlaxoSmithKline announces Swiss approval of Tyverb®, a new oral treatment for advanced breast cancer

23 May 2007
GlaxoSmithKline plc - results of AGM

22 May 2007
alli™ debuts through the alli Experience

21 May 2007
Cervarix™ is approved in Australia for females 10-45 years old

21 May 2007
GlaxoSmithKline responds to NEJM article on Avandia

21 May 2007
GlaxoSmithKline strongly defends its record on Avandia

17 May 2007
Sally Field addresses members of Congress about osteoporosis during national osteoporosis awareness month

11 May 2007
GlaxoSmithKline's Hib-MenCY-TT combination vaccine meets phase II study endpoints of immunogenicity and safety compared to licensed vaccines

10 May 2007
Cervarix® data show that higher levels of antibodies in the bloodstream correlate to higher levels in cervico-vaginal secretions

08 May 2007
Fabre-Kramer refiles gepirone ER with the FDA for the treatment of major depressive disorder

07 May 2007
GlaxoSmithKline's investigational DTaP-IPV combination vaccine shown to be immunogenic and well-tolerated in Phase III clinical trial

02 May 2007
GlaxoSmithKline supports World Health Organization efforts to strengthen global pandemic preparedness plans

02 May 2007
Trexima™ (sumatriptan/naproxen sodium) provided relief of both traditional and non-traditional migraine symptoms

02 May 2007
Trexima™ (sumatriptan/naproxen sodium) demonstrated efficacy across multiple migraine attacks

01 May 2007
FDA Advisory Committee finds substantial evidence to support Advair 500/50 in reducing COPD exacerbations

01 May 2007
New data shows once a day Lamictal® XR™ is effective in treating patients with partial seizures

30 April 2007
GlaxoSmithKline and Wellcome Trust announce partnership to target drug-resistant hospital infections

27 April 2007
FDA approves once-daily Veramyst (fluticasone furoate) Nasal Spray for treatment of seasonal and year-round allergy symptoms in adults and children as young as two years

25 April 2007
Results announcement for the first quarter 2007

18 April 2007
GlaxoSmithKline receives Japanese approval for two major new product opportunities: Seretide/Advair and Arixtra

18 April 2007
Community health charities receive £265,000 in recognition of their work from GlaxoSmithKline

17 April 2007
Cervarix®, GSK cervical cancer candidate vaccine, demonstrates 100 percent protection against precancerous lesions caused by cancer-causing human papillomavirus types 16 & 18 for more than five years

12 April 2007
GSK initiates repeat dosing study of its novel oral platelet growth factor, eltrombopag, in ITP

12 April 2007
GSK announces FDA approval of Altabax (retapamulin ointment), 1%

09 April 2007
GSK and Adolor announce preliminary results from phase 3 Safety study of Alvimopan (Entereg/Entrareg)

03 April 2007
Once daily, extended-release ropinirole improves Parkinson's symptoms in patients not optimally controlled with levodopa

03 April 2007
Trexima (sumatriptan/naproxen sodium) superior efficacy data published in JAMA

02 April 2007
GlaxoSmithKline KK seeks approval in Japan for lapatinib, a new treatment for breast cancer

02 April 2007
FDA approves accelerated dosing schedule for GlaxoSmithKline's Twinrix

30 March 2007
GlaxoSmithKline files meningococcal conjugate vaccine

29 March 2007
GlaxoSmithKline submits biologics license application to US Food and Drug Administration for Cervarix

29 March 2007
GlaxoSmithKline appoints Zhi Hong to head infectious-diseases research centre

26 March 2007
New study indicates nicotine patches may be safe for helping patients with coronary artery disease to quit smoking

23 March 2007
GlaxoSmithKline announces Altargo receives positive opinion in Europe for treatment of impetigo and other skin infections

22 March 2007
GSK giving figures exceed £300 million for fourth year running: medicines for Lymphatic Filariasis elimination valued at £16 million

22 March 2007
GSK announces nationwide availability of once-a-day Coreg CR for the treatment of three key cardiovascular conditions

20 March 2007
FiberChoice plus multivitamins issues allergy alert

13 March 2007
FDA approves Tykerb (lapatinib) in combination with Xeloda (capecitabine) for the treatment of advanced or metastatic breast cancer in women who have progressed on prior therapy

09 March 2007
New JACC analysis details cardiovascular protective benefits of carvedilol in heart failure patients

05 March 2007
New studies indicate GSK's pre-pandemic influenza vaccine can protect against different strains of H5N1

01 March 2007
Study published in New England Journal of Medicine: Vaccine 95.5% effective against neglected hepatitis E

27 February 2007
New data show fluticasone furoate nasal spray effectively treated nasal symptoms of allergic rhinitis

26 February 2007
GSK initiates first global Phase III study of Tykerb (lapatinib) in head and neck cancer

21 February 2007
Landmark study shows important benefits of Seretide treatment for patients with fatal lung disease, COPD

20 February 2007
GlaxoSmithKline acquires exclusive rights to over-the-counter orlistat for markets outside the US from Roche Group

20 February 2007
OFT market study into the Pharmaceutical Price Regulation Scheme

16 February 2007
GlaxoSmithKline successfully completes tender offer for shares of Praecis Pharmaceuticals

16 February 2007
GlaxoSmithKline Diseases of the Developing World ad campaign receives industry award

13 February 2007
WHO awards prequalification status to GSK rotavirus vaccine

13 February 2007
GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B in systemic lupus erythematosus

13 February 2007
GlaxoSmithKline offers new tools to help patients get free medicines

12 February 2007
GlaxoSmithKline plc announces change to the Board of Directors

09 February 2007
GlaxoSmithKline commends $1.5 billion advance market commitment for pneumococcal vaccines

08 February 2007
Full-year results announcement 2006

08 February 2007
GlaxoSmithKline and XenoPort announce agreement on late-stage compound for RLS and neuropathic pain

08 February 2007
GlaxoSmithKline and Fabre-Kramer Pharmaceuticals enter global agreement for new treatment of major depressive disorder

07 February 2007
FDA approves alli (orlistat 60 mg capsules) over-the-counter

07 February 2007
GlaxoSmithKline accepts shares in tender offer for shares of Praecis Pharmaceuticals and commences subsequent offering period

02 February 2007
GlaxoSmithKline receives approvable letter for new indications for Arixtra (fondaparinux sodium) injection

02 February 2007
Valtrex (valacyclovir) - US patent litigation update

29 January 2007
GlaxoSmithKline statement - BBC Panorama - 29 January 2007

29 January 2007
GlaxoSmithKline files its new pre-pandemic influenza vaccine in Europe

18 January 2007
GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines

17 January 2007
GlaxoSmithKline awarded $63 million HHS contract for pandemic vaccine research and development: Company begins government and retail shipments of its antiviral Relenza

16 January 2007
GlaxoSmithKline receives first European approval for Wellbutrin XR

09 January 2007
GlaxoSmithKline commences tender offer to acquire Praecis Pharmaceuticals